If Sanofi opts in to the other project, Regeneron will lead MUC16xCD3 bispecific development and marketing in the US. The companies will share development costs and profits.

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...